NASDAQ:AMGN Amgen (AMGN) Stock Price, News & Analysis $315.83 +0.93 (+0.30%) (As of 04:02 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Amgen Stock (NASDAQ:AMGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$314.02▼$317.2450-Day Range$312.86▼$337.3852-Week Range$249.70▼$346.85Volume766,494 shsAverage Volume2.43 million shsMarket Capitalization$169.42 billionP/E Ratio54.36Dividend Yield2.85%Price Target$332.55Consensus RatingModerate Buy Company OverviewAmgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California. Established in 1980 by William Bowes from Cetus Corporation and Winston Salser from UCLA, Amgen is now one of the world's largest independent biotechnology companies, with over 24,000 employees worldwide. The company's primary focus is on molecular biology and biochemistry, intending to provide healthcare solutions based on recombinant DNA technology.Neulasta, one of Amgen's most prominent selling product lines, is used to prevent infections in patients undergoing cancer chemotherapy. Enbrel is another famous selling product line for Amgen, used in the treatment of rheumatoid arthritis and other autoimmune diseases. The company's other products have various applications in treating cancer, anemia, osteoporosis and other conditions.Amgen has a rich history of strong leadership, with the appointment of several successful CEOs since its inception. Robert A. Bradway is the current CEO and was brought to Amgen in May 2012 following his predecessor's retirement. Bradway has led the company to new heights with strategic acquisitions and partnerships.Amgen has made at least five major corporate acquisitions. In 2019, the company announced it would acquire Nuevolution AB and the Otezla drug program from Celgene and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. These acquisitions have strengthened Amgen's drug pipeline and provided new revenue streams for the company. In March 2021, Amgen announced its plans to acquire Five Prime Therapeutics and its lead research drug candidate, bemarituzumab, for $1.9 billion. It also agreed to acquire Rodeo Therapeutics for up to $720 million. These acquisitions are part of the company's ongoing efforts to expand its drug pipeline and bring new treatments to patients.In 2012, Amgen faced legal issues when it pleaded guilty and agreed to pay $150 million in criminal penalties and $612 million in damages to resolve 11 related whistleblower complaints. Amgen has also faced criticism for lobbying for a two-year extension on sales of drugs, including Sensipar, without government controls, which will cost taxpayers an estimated $500 million. However, the company remains committed to providing innovative and effective healthcare solutions for patients.Amgen's success can be attributed to its commitment to innovation, strategic acquisitions, strong partnerships and top-end leadership. The company's impressive portfolio of products and its commitment to the community has solidified Amgen's position as a leader in biopharmaceuticals.Written by Jeffrey Neal JohnsonRead More… $5k to $1.3m in just 3 trades (Ad)It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.Register for the imminent briefing here. Amgen Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks89th Percentile Overall ScoreAMGN MarketRank™: Amgen scored higher than 89% of companies evaluated by MarketBeat, and ranked 121st out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.3 / 5Analyst RatingModerate Buy Consensus RatingAmgen has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 11 buy ratings, 11 hold ratings, and 1 sell rating.Amount of Analyst CoverageAmgen has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Amgen's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.34% Earnings GrowthEarnings for Amgen are expected to grow by 5.34% in the coming year, from $19.49 to $20.53 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amgen is 54.20, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Amgen is 54.20, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 134.46.Price to Earnings Growth RatioAmgen has a PEG Ratio of 2.86. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAmgen has a P/B Ratio of 27.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Amgen's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.83% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Amgen has recently increased by 9.00%, indicating that investor sentiment is decreasing significantly. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldAmgen pays a meaningful dividend of 2.84%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAmgen has been increasing its dividend for 13 years.Dividend CoverageThe dividend payout ratio of Amgen is 128.57%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Amgen will have a dividend payout ratio of 43.84% next year. This indicates that Amgen will be able to sustain or increase its dividend.Read more about Amgen's dividend. Sustainability and ESG3.9 / 5Environmental Score-2.42 Percentage of Shares Shorted1.83% of the float of Amgen has been sold short.Short Interest Ratio / Days to CoverAmgen has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Amgen has recently increased by 9.00%, indicating that investor sentiment is decreasing significantly. News and Social Media3.1 / 5News Sentiment0.64 News SentimentAmgen has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 38 news articles for Amgen this week, compared to 21 articles on an average week.Search InterestOnly 30 people have searched for AMGN on MarketBeat in the last 30 days. This is a decrease of -3% compared to the previous 30 days.MarketBeat Follows22 people have added Amgen to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amgen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.69% of the stock of Amgen is held by insiders.Percentage Held by Institutions76.50% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amgen's insider trading history. AMGN Stock News HeadlinesHow I’d Invest $100K Today to Get Filthy RichHow would I invest a chunk of money today? Say $10K or even $100K? I’d load up on dividend magnet stocks, sit back and watch Fed Chair Jay Powell pumpOctober 8, 2024 | marketbeat.comAMGEN ANNOUNCES WEBCAST OF 2024 THIRD QUARTER FINANCIAL RESULTSOctober 24 at 4:00 PM | prnewswire.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.October 24, 2024 | Insiders Exposed (Ad)Denosumab (Prolia & Xgeva) by Amgen Biosimilars Pipeline Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D StageOctober 24 at 9:55 AM | globenewswire.comAmgen put volume heavy and directionally bearishOctober 23 at 8:36 PM | markets.businessinsider.comBuy Rating on Amgen: Strategic Positioning and Pavblu’s Market PotentialOctober 23 at 3:35 PM | markets.businessinsider.comAmgen (AMGN) Receives a Buy from Piper SandlerOctober 23 at 3:35 PM | markets.businessinsider.comAmgen Inc. (NASDAQ:AMGN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 23 at 4:25 AM | americanbankingnews.comSee More Headlines AMGN Stock Analysis - Frequently Asked Questions How have AMGN shares performed this year? Amgen's stock was trading at $288.02 at the beginning of 2024. Since then, AMGN stock has increased by 9.3% and is now trading at $314.93. View the best growth stocks for 2024 here. How were Amgen's earnings last quarter? Amgen Inc. (NASDAQ:AMGN) released its quarterly earnings results on Tuesday, August, 6th. The medical research company reported $4.97 earnings per share for the quarter, missing the consensus estimate of $5.01 by $0.04. The business's revenue for the quarter was up 20.1% compared to the same quarter last year. Read the conference call transcript. Does Amgen have any subsidiaries? The following companies are subsidiaries of Amgen: TeneoBio, Five Prime Therapeutics, Rodeo Therapeutics, Otezla, Nuevolution, Catherex, Catherex, and more. Who are Amgen's major shareholders? Top institutional investors of Amgen include Pathway Financial Advisers LLC (0.83%), International Assets Investment Management LLC (0.47%), Assenagon Asset Management S.A. (0.29%) and Raymond James & Associates (0.18%). Insiders that own company stock include Amgen Inc, Murdo Gordon, Jonathan P Graham, Robert Eckert, Nancy A Grygiel, Nancy A Grygiel and R Sanders Williams. View institutional ownership trends. How do I buy shares of Amgen? Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Amgen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amgen investors own include NVIDIA (NVDA), Meta Platforms (META), Chevron (CVX), Verizon Communications (VZ), Bristol-Myers Squibb (BMY), JPMorgan Chase & Co. (JPM) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/06/2024Dividend Payable8/06/2024Ex-Dividend for 8/6 Dividend8/16/2024Today10/24/2024Next Earnings (Confirmed)10/30/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:AMGN CUSIP03116210 CIK318154 Webwww.amgen.com Phone(805) 447-1000Fax805-447-1010Employees26,700Year Founded1980Price Target and Rating Average Stock Price Target$332.55 High Stock Price Target$405.00 Low Stock Price Target$215.00 Potential Upside/Downside+5.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage24 Analysts Profitability EPS (Most Recent Fiscal Year)$7.00 Trailing P/E Ratio54.20 Forward P/E Ratio16.16 P/E Growth2.86Net Income$6.72 billion Net Margins10.12% Pretax Margin11.40% Return on Equity161.72% Return on Assets10.81% Debt Debt-to-Equity Ratio9.64 Current Ratio1.26 Quick Ratio0.89 Sales & Book Value Annual Sales$30.93 billion Price / Sales5.46 Cash Flow$25.75 per share Price / Cash Flow12.23 Book Value$11.65 per share Price / Book27.03Miscellaneous Outstanding Shares536,435,000Free Float533,621,000Market Cap$168.92 billion OptionableOptionable Beta0.61 Social Links This page (NASDAQ:AMGN) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredAre You Holding the Winning Hand in the Copper Market?Are You Holding the Winning Hand in the Copper Market?Market JAR | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAccording to Steven Lubka, head of a private equity firm with over $250M in assets under management, "Bitcoin ...Crypto 101 Media | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Amgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.